Proteomics and Metabolomics of Body Fluid in Patients With Narcolepsy

Launched by QILU HOSPITAL OF SHANDONG UNIVERSITY · Feb 19, 2024

Keywords

ClinConnect Summary

This clinical trial is studying narcolepsy, a chronic sleep disorder that can cause excessive daytime sleepiness, sudden muscle weakness (called cataplexy), and other symptoms like sleep paralysis and vivid dreams. The researchers want to understand how changes in body fluids, such as proteins and metabolites, might relate to the causes of narcolepsy. This information could help improve the understanding and diagnosis of the condition, which is often missed or misdiagnosed due to its varied symptoms.

To participate in this study, you need to be between 18 and 65 years old and meet specific diagnostic criteria for narcolepsy as outlined by sleep disorder guidelines. However, individuals with other sleep disorders, certain neurological or mental health conditions, or those on specific medications will not be eligible. If you join the trial, you'll undergo tests to analyze your body fluids, which will help researchers learn more about narcolepsy. This study is currently recruiting participants, and everyone, regardless of gender, is welcome to apply.

Gender

ALL

Eligibility criteria

• • Inclusion Criteria
• • All patients met the diagnostic criteria of the International Classification of Sleep Disorders, Third edition (ICSD-3).
• • Exclusion Criteria
• • primary hypersomnia or hypersomnia due to shift work, sleep deprivation and other sleep rhythm disturbances;
• • excessive sleep due to drug abuse;
• • suffering from Parkinson's disease, Alzheimer's disease and other nervous system diseases and mental diseases;
• • complicated with heart, lung, liver, kidney, blood endocrine system and other basic diseases, or acute chronic infection in a short period of time;
• • Use of sedatives, hypnotics, antidepressants, lithium and dopamine receptor antagonists for two weeks before examination;
• • patients who cannot cooperate with PSG and MSLT due to various factors.